EFTA01187552Set 9
2012-12-0213p8,405w
report described a trial that compared three diabetes drugs and
concluded that Avandia, the company's new drug, performed best. "We now have clear evidence from a large international
study ... that the initial use of [Avandia] is more effective than standard therapies," a senior vice president of
GlaxoSmithKline, Lawson Macartney, said in a news release. The trial had been funded ... grants or consultant fees from the firm.
Whether these ties altered the report on Avandia may be impossible for readers to know. But while sorting through the data
from more
https://www.justice.gov/epstein/files/DataSet%209/EFTA01187552.pdf